Revised SPC: Pharmorubicin (epirubicin) 2 mg/ml Solution for Injection or Infusion

SPC updated to advise that trastuzumab may persist in circulation for up to 7 months, therefore physicians should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible, and if not, cardiac function should be monitored carefully.


electronic Medicines compendium